Atezolizumab showed modest response rates in NSCLC patients previously treated with PD-1 inhibitors, with a suggested baseline response rate of 10% for new ICI combinations. The study's primary ...

Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma patients. Cytokine release syndrome occurred in 70% of patients, with lower ...

Role of induction chemotherapy in locally advanced oropharyngeal carcinoma in Indian population. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...

Rina-S showed a 50% confirmed response rate in heavily pretreated advanced endometrial cancer patients, with two complete responses observed. The phase 1/2 results support Rina-S as a potential ...

In today’s crowded marketing landscape, getting and holding attention is harder than ever. Marketers are juggling email, social, paid search, video, and more, each with its own metrics, costs, and ...

BARCELONA — Restarting an anti-CGRP monoclonal antibody (mAb) for migraine prevention after a gap in treatment often leads to a lower efficacy rate in the second treatment period, a new study suggests ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...

Zongertinib shows a 71% response rate and 12.4 months median progression-free survival in HER2-mutated NSCLC, with minimal adverse events. Patient-reported outcomes indicate rapid improvement in ...

Genmab A/S ( Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with ...

KNOWLEDGE of many facets of American life comes from surveys. Every ten years the Census Bureau asks adults to tally themselves and their demographic information in an online or mail-in form: a survey ...